Professor Peter Johnson, NHS National Clinical Director for Cancer and chair of the Office for Life Sciences (OLS)

A GP in a market town sees a 58-year-old woman for the third time in four months. She describes persistent bloating and a vague discomfort after meals. The examination is unremarkable, and routine blood tests reveal nothing. The doctor faces an uncomfortable decision: make an urgent cancer referral, taking up a scarce diagnostic appointment and leaving the patient facing a fortnight of anxiety, or wait, knowing that apparently ordinary symptoms can sometimes conceal ovarian or pancreatic cancer. Only 2 to 6 per cent of urgent suspected cancer referrals currently result in a diagnosis. Most prove unnecessary. The occasional case that is missed, however, can return months later, when the disease is considerably harder to treat.

This is the consultation the STRIDE trial, launched this week across at least 200 practices in England, hopes to change. More than 20,000 patients aged 45 and over who present with persistent abdominal symptoms will be offered an additional blood test alongside their routine investigations. Most of the tests were developed at the University of Birmingham and use techniques including artificial intelligence and protein measurement to detect signals associated with different cancers and indicate where in the body they may have originated. A positive result will inform the GP's decision about an urgent referral; it will not constitute a diagnosis. The Government has committed up to £8.49 million through the National Institute for Health and Care Research and the Office for Life Sciences. Professor Peter Johnson, NHS England's National Clinical Director for Cancer, welcomed the research as an opportunity to address one of the most persistent difficulties in cancer care. He has described abdominal cancer detection as notoriously difficult because its symptoms can easily be mistaken for less serious conditions. Johnson said the trial would establish whether blood tests could help GPs direct the right patients towards investigations sooner, while emphasising the need for evidence before the technology is adopted across the NHS.

The design deserves more attention than the headline. Multi-cancer blood testing has so far been judged mainly as a screening tool for people without symptoms, and the results have been mixed. The NHS-Galleri trial enrolled more than 140,000 asymptomatic adults but failed to reduce the combined number of stage III and IV cancers, its primary endpoint, although fewer stage IV cancers were diagnosed in the tested group. Testing a healthy population means looking for rare disease among large numbers of people who have none, increasing the risk of false alarms and detecting cancers that might never have caused harm. Symptomatic patients in general practice present a different statistical problem. Their likelihood of having cancer before testing is higher, and the blood test supplements a clinical judgement the GP is already making. STRIDE therefore examines a version of the technology with a stronger prospect of finding a practical place in routine care.

The potential benefit will be felt first in diagnostic capacity. Urgent suspected cancer pathways depend on endoscopy and cross-sectional imaging, both of which remain scarce, while the 62-day cancer treatment standard has been missed consistently for years. A test that increases the proportion of referrals resulting in a diagnosis could free appointments for patients who need them. One that simply adds another hurdle will do the opposite. The outcome will depend heavily on how GPs interpret the results. If a positive blood test prompts referrals for patients who might otherwise have been reassured, the pathway could face a fresh surge in demand. If a negative result is treated as permission to wait, patients with persistent symptoms risk being given false reassurance. Johnson's wider work on NHS diagnostic services has recognised the importance of improving access to investigations, including through the expansion of Community Diagnostic Centres. His focus on cancer waiting-time standards has also highlighted the need for prompt diagnosis while recognising that most patients urgently referred for suspected cancer will not ultimately have the disease. These are precisely the competing pressures STRIDE must address. Radiology and endoscopy services cannot expand overnight when trial results arrive. Any changes to referral pathways must be planned alongside workforce and diagnostic capacity. The safeguards built into the research, and the clinical safety-netting around it, will shape its findings as much as the accuracy of the tests themselves.

The sample matters for another reason. Investigators have designed the trial to include practices in inner cities, coastal towns and rural areas, while people in the most deprived communities remain more likely to receive a cancer diagnosis following an emergency presentation. A tool that works only in well-resourced practices, where appointments are longer and continuity of care is easier to maintain, could deepen an existing divide. General practice is already being asked to absorb research activity, new diagnostic decisions and the digital reconfiguration of its work while appointment demand remains heavy. Recruiting 20,000 patients is a substantial undertaking for practice teams. The research infrastructure supporting the trial deserves as much scrutiny as the science.

Ministers present STRIDE as part of the National Cancer Plan and the ambition to make Britain Europe's leading life sciences economy by 2030. Both are legitimate priorities, although they carry different pressures. Commercial developers are keen to use the NHS as a validation platform, and the health service has the patient population, clinical data and scale to provide one. Johnson's role as Chair of the Office for Life Sciences Cancer Goal places him close to the wider effort to bring research, industry and NHS services together. But successful collaboration must not allow commercial enthusiasm to run ahead of clinical evidence. Commissioners and national bodies must ensure that approval rests on clinical utility, including patient outcomes and the effect on referral pathways, rather than analytical performance alone. Developers should expect rigorous cost-effectiveness assessments to follow. The Treasury will want to know who pays for the tests once the evidence arrives, and that decision will determine whether the technology reaches patients beyond the trial sites. NHS leaders should begin modelling diagnostic demand under both favourable and unfavourable outcomes. A decision on national rollout could arrive considerably sooner than the capacity needed to support it.

The value of STRIDE will ultimately lie in the answer it provides to an operational question as much as a clinical one. Whether a blood test can recognise cancer is a matter for the laboratory. Whether it can improve a GP's judgement and spare the health service thousands of fruitless referrals will be settled in consulting rooms and diagnostic departments. Professor Johnson's call for evidence before wider adoption is therefore an important one. A successful trial would still leave the NHS with the difficult task of making its findings work in practice. The woman in the market town deserves a better answer than the arithmetic currently offers. The health service should start preparing to deliver it.